

North Central Cancer Treatment Group

N04C2, An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR[®] Depot) for Symptomatic Ascites in Cancer Patients

Addendum 4 – November 21, 2008

Summary

- Study statistician has been updated.
- Clarification made to the Schema.
- Editorial/administrative changes.

A replacement protocol is provided. Please replace the current copy with the one attached. Please keep this addendum with your protocol.

Title page Updated to reflect **Rui Qin, Ph.D** replaces ~~Jeff Sloan, Ph.D.~~ as the study statistician and revised NCI version date.


Protocol Resources

Page 2: The fax number for Monica Hansen has been updated as follows:
Fax: (507/~~284-1902266-7240~~)

Melissa Hogston replaces ~~Jeanette Lovas~~ as the NCCTG Member Clinical Research Associate.

Tracee Shevlin replaces ~~Laura Denton~~ as the NCCTG *Research Base* Protocol Development Coordinator.

Schema A clarification has been made to the schema to reflect that dosing is monthly, rather than q 30 days, as indicated below:



*Octreotide/placebo may be administered monthly up to 2 years.